Caryn Lerman, Director of Norris Comprehensive Cancer Center at Keck Medicine of USC, shared a post on LinkedIn:
“Heinz Josef Lenz, Deputy Director for Research Programs at USC Norris and Professor of Medicine and Cancer Biology at the Keck School of Medicine of USC, provided a presentation at the American Society of Clinical Oncology annual meeting during which he provided expanded data from the CheckMate clinical trial, a practice-changing trial that led to the FDA approving a new first line combination therapy for patients with microsatellite instability-high/DNA mismatch repair colorectal cancer.”
Read OncoDaily’s Special Articles from ASCO25:
Highlights from ASCO 2025 Day 1
Highlights from ASCO 2025 Day 2
Highlights from ASCO 2025 Day 3
Highlights from ASCO 2025 Day 4
